A study from the Women’s Health Initiative involving postmenopausal women receiving hormone therapy with conjugated equine estrogens alone or combined with medroxyprogesterone acetate found long-term changes in cardiovascular biomarkers. While hormone therapy showed favorable effects on several cardiovascular biomarkers, including lower LDL cholesterol and lipoprotein(a) levels, it also led to increased triglycerides and clotting-related factors, and did not reduce the risk of coronary heart disease. The study emphasizes the importance of considering the overall cardiovascular outcomes when weighing the benefits and risks of hormone therapy.

Source: Obstetrics and Gynecology